• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Study: Vision loss treatment linked to higher risk of glaucoma surgery

March 17, 2017 By Sarah Faulkner

Study: Vision loss treatment linked to higher risk of glaucoma surgery
Photo credit: Laitr Keiows

Researchers from the University of British Columbia found that patients with age-related macular degeneration who had at least 7 eye injections per year had a heightened risk of having glaucoma surgery. The team’s findings were published this week in JAMA Ophthalmology.

Patients with wet age-related macular degeneration and diabeteic macular edema, common causes of vision loss, are often treated with intravitreous injections of anti-vascular endothelial growth factor. Previous work has established that these treatments improve visual outcomes for many patients.

Although intravitreous injections of anti-VEGF agents increase the risk of elevated intraocular pressure, researchers didn’t know if there was a link between treatment and the risk of developing moderate to advanced glaucoma.

The team identified 74 cases of glaucoma surgery and 740 controls. They found that having 7 or more anti-VEGF injections each year was associated with a significantly higher risk of glaucoma surgery.

“Clinicians should be aware of the potential association of repeated, recent intravitreous anti-VEGF injections for diseases, such as exudative AMD, with subsequent need for glaucoma surgery,” the authors wrote.

Earlier in March, researchers from the University of Southern California’s Roski Eye Institute described a micropump that can be implanted directly into the eye and deliver a predetermined dose of the diabetic macular edema drug ranibizumab.

Current treatments for glaucoma are traditionally delivered using eye drops. But studies show that some patients stop taking their prescription glaucoma eye drops after 1 year, according to the team of researchers. Patients can be uncomfortable using the eye drops or they forget to consistently take their prescribed medication.

To address the treatment’s noncompliance issue, the researchers developed a micropump that includes a reservoir for medication. Dosage and frequency can be controlled using a wirelessly-connected device, according to the team.

Filed Under: Featured, Optical/Ophthalmic, Research & Development, Surgical Tagged With: University of British Columbia

IN CASE YOU MISSED IT

  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS